GSK (GSK, Financial) has announced a positive decision from the Advisory Committee on Immunization Practices (ACIP), which has extended its recommendation for the use of RSV vaccines to include GSK’s AREXVY. This update encompasses adults aged 50 to 59 who have a heightened risk of severe RSV disease. This demographic includes individuals with underlying health conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and heart disease, as well as those residing in care facilities.
The ACIP's recent vote expands upon their earlier recommendation from June 2024, which approved RSV vaccines for adults aged 60 to 74 at increased risk, along with all individuals aged 75 and over. AREXVY is designed to prevent lower respiratory tract disease (LRTD) associated with RSV, now recommended for both the 60-plus age group and at-risk adults aged 50 through 59.
Research indicates that RSV is responsible for approximately 42,000 hospitalizations annually among U.S. adults aged 50 to 64. Those with pre-existing medical conditions, such as COPD, asthma, heart failure, and diabetes, face a higher risk of severe outcomes from RSV infections. The virus can worsen these conditions, potentially leading to severe complications like pneumonia, hospitalization, or even death.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for GSK PLC (GSK, Financial) is $38.89 with a high estimate of $45.00 and a low estimate of $33.96. The average target implies an upside of 9.94% from the current price of $35.37. More detailed estimate data can be found on the GSK PLC (GSK) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, GSK PLC's (GSK, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for GSK PLC (GSK, Financial) in one year is $41.68, suggesting a upside of 17.84% from the current price of $35.37. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the GSK PLC (GSK) Summary page.
